Kairos Pharma, Ltd. (KAPA) Price & Analysis

Compare

126 Followers

KAPA Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.40 - $3.25

Previous CloseN/A

Volume680.77K

Average Volume (3M)1.58M

Market Cap

$27.17M

Enterprise ValueN/A

Total Cash (Recent Filing)N/A

Total Debt (Recent Filing)N/A

Price to Earnings (P/E)―

Beta0.46

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.20

Shares Outstanding20,743,765

10 Day Avg. Volume652,491

30 Day Avg. Volume1,580,208

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

$8.00

Price Target Upside589.66% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

Bulls Say, Bears Say

Bulls Say

Efficacy ResultsResults from the ongoing P2 study showed a median progression-free survival of over 13 months, suggesting potential effectiveness of ENV-105 in re-sensitizing tumors to anti-androgen therapy.

Market OpportunityENV-105 could be used to improve or extend the efficacy of blockbuster drugs in their respective indications, providing a unique market opportunity.

Safety ProfileKairos reported positive interim safety data from the first 10 patients enrolled in its ongoing P2 trial of ENV-105 + Erleada in mCRPC, with no dose-limiting toxicities or unexpected adverse effects observed.

Bears Say

Stock Price MovementKAPA shares are down ~16% on the news, which is believed to stem from the recent run-up.

Stock VolatilityKAPA shares have increased by over 150% since early June, attributed to positive P2 safety results, a strong biotech sector performance, and anticipation of interim data in prostate cancer.

Kairos Pharma, Ltd. News

Kairos Pharma announces interim efficacy analysis of ENV105

Kairos Pharma (KAPA) announced efficacy data from its ongoing Phase 2 clinical trial of ENV105 in patients with...

24d ago

KAPA

Promising Developments in Kairos Pharma’s Lead Candidate ENV-105 Drive Buy Rating

Maxim Group analyst Jason McCarthy has maintained their bullish stance on KAPA stock, giving a Buy rating on...

4d ago

KAPA

Kairos Pharma to Present at ESMO Congress 2025

Kairos Pharma, Ltd. ( ($KAPA) ) has provided an announcement. On October 7, 2025, Kairos Pharma announced its...

5d ago

KAPA

Promising Phase 2 Results and Safety Profile of ENV-105 Bolster Buy Rating for Kairos Pharma

Kairos Pharma, Ltd., the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Joseph Pantginis...

20d ago

KAPA

Kairos Pharma Reports Positive Phase 2 Trial Results

Kairos Pharma, Ltd. ( ($KAPA) ) has issued an update. On September 18, 2025, Kairos Pharma announced positive...

24d ago

KAPA

Kairos Pharma’s Promising Developments and Positive Trial Data Reinforce Buy Recommendation

Analyst Jason McCarthy of Maxim Group reiterated a Buy rating on Kairos Pharma, Ltd., retaining the price target...

25d ago

KAPA

Kairos Pharma to Host KOL Event on Phase 2 Trial

Kairos Pharma, Ltd. ( ($KAPA) ) has shared an announcement. On September 11, 2025, Kairos Pharma announced it...

1M ago

KAPA

Kairos Pharma Presents Phase 1 Data at Conference

Kairos Pharma, Ltd. ( ($KAPA) ) has issued an announcement. On September 3, 2025, Kairos Pharma announced its...

1M ago

KAPA

Kairos Pharma: Promising Drug Pipeline and Upcoming Catalysts Drive Buy Rating

Jason McCarthy, an analyst from Maxim Group, maintained the Buy rating on Kairos Pharma, Ltd.. The associated price...

2M ago

KAPA

Optimistic Buy Rating for Kairos Pharma Driven by Promising Clinical Developments and Strong Safety Profile

In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Kairos Pharma, Ltd.,...

2M ago

KAPA

Kairos Pharma management to meet with Maxim

Meeting to be held on August 6 hosted by Maxim. Published first on TheFly – the ultimate source...

2M ago

KAPA

Why Is Kairos Pharma Stock (KAPA) Up 170% Today?

Kairos Pharma stock rallied on Tuesday after it posted positive interim safety results from a clinical trial. ...

3M ago

KAPA

Kairos Pharma announces positive safety results from Phase 2 ENV-105 trial

Kairos Pharma (KAPA) announced positive safety results from its ongoing Phase 2 clinical trial of ENV-105 in patients...

3M ago

KAPA

Kairos Pharma files to sell 16.29M shares of common stock for holders

06:05 EDT Kairos Pharma (KAPA) files to sell 16.29M shares of common stock for holders Published first on...

6M ago

KAPA

KAPA FAQ

What was Kairos Pharma, Ltd.’s price range in the past 12 months?

Kairos Pharma, Ltd. lowest stock price was $0.40 and its highest was $3.25 in the past 12 months.

What is Kairos Pharma, Ltd.’s market cap?

Kairos Pharma, Ltd.’s market cap is $27.17M.

When is Kairos Pharma, Ltd.’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Kairos Pharma, Ltd.’s earnings last quarter?

Currently, no data Available

Is Kairos Pharma, Ltd. overvalued?

According to Wall Street analysts Kairos Pharma, Ltd.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Kairos Pharma, Ltd. pay dividends?

Kairos Pharma, Ltd. does not currently pay dividends.

What is Kairos Pharma, Ltd.’s EPS estimate?

Kairos Pharma, Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Kairos Pharma, Ltd. have?

Kairos Pharma, Ltd. has 20,743,765 shares outstanding.

What happened to Kairos Pharma, Ltd.’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Kairos Pharma, Ltd.?

Currently, no hedge funds are holding shares in KAPA

Company Description

Kairos Pharma, Ltd.

Kairos Pharma, Ltd. operates as a clinical-stage biopharmaceutical company that develops therapeutics for cancer patients. Its therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. Kairos Pharma, Ltd. was formerly known as NanoGB13, Inc. and changed its name to Kairos Pharma, Ltd. in July 2016. The company was incorporated in 2013 and is based in Los Angeles, California.

KAPA Stock 12 Month Forecast

Average Price Target

$8.00

▲(589.66% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6":"$6","13":"$13","-1":"-$1","2.5":"$2.5","9.5":"$9.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$12.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$8.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$4.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,2.5,6,9.5,13],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Mar<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.13,1.9661538461538461,2.8023076923076924,3.638461538461539,4.474615384615385,5.310769230769231,6.146923076923078,6.983076923076924,7.81923076923077,8.655384615384616,9.491538461538461,10.32769230769231,11.163846153846155,{"y":12,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.13,1.6584615384615384,2.186923076923077,2.715384615384615,3.2438461538461536,3.772307692307692,4.30076923076923,4.829230769230769,5.357692307692307,5.886153846153846,6.414615384615384,6.943076923076923,7.471538461538461,{"y":8,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.13,1.3507692307692307,1.5715384615384616,1.7923076923076922,2.013076923076923,2.233846153846154,2.4546153846153844,2.6753846153846155,2.896153846153846,3.1169230769230767,3.3376923076923077,3.5584615384615383,3.779230769230769,{"y":4,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.46,"date":1717200000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.46,"date":1719792000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.46,"date":1722470400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.46,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1.36,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1.36,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.19,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.92,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.59,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.7,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.92,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.41,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.13,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >